Podcasts about Barata

Azeredo Lopes considera que a Ucrânia atingiu um novo patamar de eficácia com meios baratos. Sublinha que a NATO está obsoleta e os EUA têm stocks baixos devido ao uso de armas caras contra drones.See omnystudio.com/listener for privacy information.

Bastará con anunciar: “Esta es la versión del Gobierno”. La frase servirá como fuente, aval y seguro contra accidentes. No exige investigar, contrastar ni documentar. Esta será una verdad más barata.

Neste episódio do De Dono para Dono, nossos sócios Julian e Alexandre compartilham suas percepções sobre o ambiente de negócios na China após visitarem um cliente no país. No bate-papo, exploramos temas como o avanço dos superapps, meritocracia baseada em resultados, verticalização industrial, o papel de um governo desenvolvimentista, os desafios e as oportunidades do M&A internacional, entre muitos outros assuntos. Se você se interessa por empreendimento e tecnologia, este episódio é para você! Conheça a Auddas e descubra como podemos ajudar a alcançar o sucesso:https://auddas.com/https://www.youtube.com/@auddashttps://www.instagram.com/juliantoniolihttps://www.linkedin.com/company/auddas-consulting/https://open.spotify.com/show/0Txf0LYFaLITDaWoyHcseW?si=d020fd9381c147b3 Onde você pode encontrar a Julian:https://www.instagram.com/juliantonioli/ https://www.linkedin.com/in/juliantonioli/ Onde você pode encontrar o Alexandre:https://www.instagram.com/alechavesconselheiro/ https://www.linkedin.com/in/alexandre-chaves-conselheiro/

TUTAMÉIA entrevista o diplomata cubano Pedro Monzón Barata, ex-cônsul geral de Cuba em São Paulo e atualmente atuando em Havana como pesquisador do Centro de Pesquisa em Política Internacional do Ministério das Relações Exteriores.Inscreva-se no TUTAMÉIA TV e visite o site TUTAMÉIA, https://tutameia.jor.br, serviço jornalístico criado por Eleonora de Lucena e Rodolfo Lucena.Acesse este link para entrar no grupo AMIG@S DO TUTAMÉIA, exclusivo para divulgação e distribuição de nossa produção jornalística: https://chat.whatsapp.com/Dn10GmZP6fV...

Neste episódio do Na Trilha da Coragem, Carla Brandão recebe sua mestra, a neurocientista, professora e consultora corporativa Dra. Carla Tieppo. Pioneira na aplicação da neurociência na educação e nas organizações, ela traz um olhar cirúrgico e sem rodeios sobre o comportamento humano na atualidade.Carla Tieppo abre o jogo sobre o maior perigo civilizatório atual: o consumo da "dopamina barata" gerada pelas Bets (plataformas de apostas online). Ela desconstrói a ilusão de que apostar em esportes é uma questão de "sorte", explicando a neurobiologia por trás do vício que ataca diretamente o ego e o conhecimento do apostador. Relembrando uma história pessoal impactante de quando trabalhou no caixa de uma farmácia nos anos 90, Tieppo mostra como o vício em apostas destrói vidas de forma silenciosa e galopante.O papo também traz uma perspectiva revolucionária e otimista sobre a Inteligência Artificial. Longe do pânico generalizado, a cientista explica como a IA será a grande responsável por nos fazer desacelerar, libertando o ser humano de tarefas repetitivas e permitindo focar na verdadeira saúde mental, na arte e na filosofia.

El presidente de la RFEF, antes de la semifinal, asegura en 'El Larguero' especial desde la Casa España en Dallas que Francia "hubiera preferido otro rival" y que "España es el único equipo que puede ganarles". 

Muchos creen que ganar mucho dinero es suficiente para construir libertad financiera. Pero la historia de Herbert demuestra que una empresa puede desaparecer... mientras que una buena inversión puede generar ingresos durante décadas.  En este episodio de Ingresos Reales con Bienes Raíces, Herbert comparte cómo pasó de perder un negocio que había construido durante más de 15 años a crear una estrategia inmobiliaria que hoy le permite vivir con tranquilidad.  Lo más impresionante es que compró una casa con un 33% de descuento, la transformó en 6 unidades de renta y, antes de terminar la remodelación, ya tenía 4 alquiladas.  Pero este episodio no trata solo de números. Habla de cambiar la forma de pensar, de aprender a ver oportunidades donde otros solo ven problemas y de construir un patrimonio que pueda sostener a tu familia durante muchos años.

In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Pedro Barata from Case Western Reserve University, Ohio (US). They discuss the results of the ctDNA analysis in participants with renal cell carcinoma (RCC) treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial and the potential impact of these results for clinical practice. Read the abstract of this trial to know more. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals. We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression. Key topics covered in this episode included: The role of next-generation sequencing (NGS) in guiding treatment options Choosing between dual checkpoint inhibitors and IO-TKI combinations Managing side effects associated with various treatment regimens Sequencing treatment options for patients who progress after initial therapy Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms! #KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI, #OncologyBrothers

En el Sanedrín de hoy analizamos los últimos resultados de Booking, una de las plataformas líderes del sector viajes a nivel global. La compañía ha presentado unas cifras que el mercado no ha terminado de comprar y la acción ha sufrido una caída relevante. Pero la gran pregunta es si esa reacción está justificada… o si estamos ante una nueva oportunidad en una de las mejores plataformas digitales del mundo. ¿Por qué ha caído Booking tras resultados? ¿El mercado se equivoca con Booking Holdings? ¿Sigue siendo una buena oportunidad de inversión a largo plazo o hay señales de deterioro en el negocio? En este directo repasamos las claves de sus resultados, el crecimiento de reservas, la evolución de ingresos y márgenes, los riesgos que está descontando el mercado y si la valoración actual puede ofrecer una oportunidad para inversores de largo plazo. Dos cosas que debes saber: 1 - Cada día mandamos un email con una idea, estrategia o reflexión privada para que avances más rápido en tu camino como inversor. El de hoy ya te lo has perdido, si quieres recibir el de mañana, te apuntas en: https://locosdewallstreet.com/7-errores/ 2 - Al apuntarte recibes un video titulado «7 errores fatales (muy habituales) en la selección de oportunidades en bolsa». Me da igual en lo que inviertas, tus años de experiencia o el tamaño de tu cartera. Si inviertes deberías verlo (antes de tomar una decisión de la que poder arrepentirte). Lo recibes al apuntarte en nuestra newsletter aquí: https://locosdewallstreet.com/7-errores/ ══════════════ DISCLAIMER El contenido de este canal de YouTube tiene exclusivamente fines educativos y no constituye asesoramiento financiero ni recomendaciones de inversión. Todos los temas tratados están diseñados para ayudar a los espectadores a entender mejor el mundo de las finanzas, pero las decisiones de inversión deben tomarse de forma personal y bajo la responsabilidad de cada individuo. Invertir en mercados financieros conlleva riesgos significativos debido a su complejidad y volatilidad. Es posible perder parte o la totalidad del capital invertido. Por ello, es fundamental que realices tu propio análisis antes de tomar cualquier decisión y, si lo consideras necesario, consultes con un profesional financiero acreditado. Recomendamos: - Contar con un fondo de emergencia equivalente a al menos tres meses de tus gastos básicos antes de invertir. - Analizar muy detenidamente y con precisión cualquier inversión. - En caso de duda consultes con un asesor financiero certificado por CNMV - Mantenerte alejado de promesas de rentabilidades astronómicas, dinero rápido u otros esquemas engañosos. En Locos de Wall Street, nuestra misión es fomentar una educación financiera sólida, ética y accesible para todos, ayudando a nuestros seguidores a tomar decisiones informadas y responsables. ══════════════ #Booking #BookingHoldings #BKNG #ResultadosBooking #Bolsa #Inversiones #ValueInvesting #Acciones #MercadosFinancieros #Sanedrin #LocosDeWallStreet #InversionALargoPlazo #AnalisisDeEmpresas #EmpresasDeCalidad #turismo

Neste episódio recebemos novamente Samuel Barata, atleta do Sport Lisboa e Benfica que já se tornou uma presença quase regular no podcast. A conversa arranca num momento pouco positivo: Samuel está a gravar dias depois de ter abdicado da Taça da Europa de 10.000 metros em pista, devido a uma inflamação articular na zona do sacroilíaco contraída em pleno estágio de altitude em Font-Romeu. O tema do treino em altitude em Font-Romeu abre uma reflexão sobre a mudança de paradigma em Portugal: de país onde a altitude era motivo de gozo para país onde já não ir é que levanta sobrancelhas. Samuel partilha a experiência de ter treinado ao lado de Isaac Nader, Salomé Afonso, Duarte Gomes e atletas italianos que iriam à mesma prova que ele. Um nível de polinização cruzada entre grupos que acontece mais facilmente no Quénia do que na Europa, mas que começa a normalizar-se. A conversa avança depois para o estado do atletismo nacional, com Samuel a catalogar a geração atual no meio-fundo como uma das melhores de sempre: recordes nacionais, europeus e mundiais acumulados, atletas nos 1500, 3000, 5000 e obstáculos a números que há dez anos seriam inimagináveis. Há também espaço para desmistificar o hype à volta da nutrição dos recordistas mundiais de maratona: na leitura de Samuel, é sobretudo marketing e o treino brutal que os quenianos fazem continua a ser a variável que verdadeiramente decide.O episódio fecha com aquele que foi um dos principais motivos do convite: o anúncio de um training camp no Quénia em novembro, organizado por Samuel e pelo seu treinador António Sousa, aberto a corredores amadores que queiram treinar em Iten, fazer os longos na estrada de Moiben e viver de perto a cultura do atletismo queniano. Grupos pequenos, máximo de 20 pessoas, inscrições abertas até 1 de setembro. Training Camp Samuel Barata - https://www.instagram.com/trainingcamp_samuelbarata/RecomendaçõesJakob Ingebrigtsen's Advice to Run Faster, For Non-Elites - Podcast Show (YouTube) - https://www.youtube.com/watch?v=OQeh_Pg0Nz0 Andamente - Canal (YouTube) - https://www.youtube.com/@AndamenteFitbit Air - Fitness tracker (YouTube) - https://www.youtube.com/watch?v=v4xrW2FVEq4Parcerias e como ajudarem este projeto

Mensagem de 22 de Fevereiro de 2026 de Carolina Barata com o título “Eis-me Aqui Senhor, Envia-me A Mim”.

Gnomos que têm vida própria e baratas que invadem propriedade privada

El Ministro de Hacienda y Finanzas de La Pampa, Guido Bisterfeld, detalló los anuncios presentados ante el ICOMEN para incentivar el consumo. A través de un esfuerzo tripartito entre el Banco de La Pampa, las pymes y el gobierno provincial con la exención de Ingresos Brutos, el programa Compre Pampeano busca abaratar los costos de financiación para amortiguar el impacto de la crisis en las industrias locales.

El consumo excesivo de ginebra a inicios del siglo XVIII provocó graves problemas sociales y de salud en Londres.

Bolívar aclaró que se trata de eventos realizados en recintos cerrados o de propiedad privada, como centros de convenciones y clubes, lo que técnicamente los diferencia de una manifestación en plaza pública.See omnystudio.com/listener for privacy information.

Lutz veste Insider

DTI - Baterías de sodio, una nueva tecnología para almacenar energía que promete ser más barata, abundante y sustentable by En Perspectiva

¿Sabías que el cerebro procesa una crítica o una "verdad incómoda" en la misma zona donde registra un golpe físico? En este episodio, exploramos por qué nos aferramos a lo que ya creemos y cómo la "dopamina barata" está blindando nuestras mentes contra el crecimiento. Te explico la neurobiología de la disonancia cognitiva, el peligro de las recompensas instantáneas y cómo la técnica del "Abogado del Diablo" puede salvar tu capacidad de razonar. Enlaces a nuestras redes sociales:Instagram⁠⁠⁠⁠⁠⁠⁠⁠@brainfulness.life⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@ladoctoraneuro⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠@brainfulness⁠⁠⁠⁠⁠⁠⁠Página web⁠⁠⁠⁠⁠⁠⁠www.brainfulness.life⁠⁠⁠⁠⁠⁠⏰ Secciones:(00:00) El accidente y las 96 horas de detox forzado (01:08) ¿Por qué la verdad duele como una cachetada? (03:14) El curioso efecto del acetaminofén en el dolor social (04:21) Sesgo de Confirmación: Por qué amamos que nos den la razón (07:26) El peligro de la dopamina barata y el blackout cerebral (10:51) La verdad incómoda: ¿Culpables o responsables? (12:27) Girasoles vs. Olivos: La madera densa del carácter (15:44) Técnica del Abogado del Diablo para bajar el cortisol (18:00) ¿Tu verdad es real o es solo confort emocional? El contenido de Brainfulness Podcast es educativo y no reemplaza el consejo de un profesional de la salud. Para cualquier condición médica, por favor, consulta a tu médico.

En este capítulo juntamos dos conversaciones clave: primero, los resultados de los grandes bancos, que muestran solidez en un entorno todavía incierto; y luego, una mirada a las empresas de IA, cuyo crecimiento sigue siendo potente, pero con valoraciones que se han enfriado. ¿Cómo es posible que compañías liderando la revolución tecnológica coticen con múltiplos incluso por debajo de gigantes como Walmart o Costco? Un episodio para cuestionar narrativas y entender dónde realmente está el valor hoy en el mercado.

No “Estadão Analisa” desta terça-feira, 14, Carlos Andreazza comenta as declarações da ministra Cármen Lúcia, que afirmou que o Supremo Tribunal Federal (STF) vem passando por transformações nos últimos anos, mas ainda necessita de novas reformas. A fala ocorreu durante o seminário “O Brasil na visão das lideranças públicas”, realizado na segunda-feira, 13, pela Fundação Fernando Henrique Cardoso. No evento, a ministra tratou da queda de confiança no Judiciário e mencionou possíveis mudanças no funcionamento da Corte. Em abril de 2026, o ambiente interno do STF foi marcado por atritos públicos entre Cármen Lúcia e Gilmar Mendes, evidenciando tensões entre os ministros. Mendes criticou a condução do Tribunal Superior Eleitoral (TSE) durante a gestão de Cármen, apontando demora em temas eleitorais. Por outro lado, relatos indicam incômodo da ministra com a proximidade de Mendes com Alexandre de Moraes e Flávio Dino. Assine por R$1,90/mês e tenha acesso ilimitado ao conteúdo do Estadão.Acesse: https://bit.ly/oferta-estadao O 'Estadão Analisa' é transmitido ao vivo de segunda a sexta-feira, às 7h, no Youtube e redes sociais do Estadão. Também disponível no agregador de podcasts de sua preferência. Apresentação: Carlos AndreazzaEdição/Produção: Jefferson PerlebergCoordenação: Renan PagliarusiFoto: Wilton Junior/EstadãoSee omnystudio.com/listener for privacy information.

Papo com os lasanheiros.

No episódio de hoje do Genial Analisa, recebemos Antônio Barreto, head de análise da Verde Asset, uma das gestoras mais respeitadas do país. Vamos mergulhar na estratégia de quem observa o mercado com cautela e precisão para entender: com a alta recente, ainda faz sentido falar em "Bolsa barata"?Barreto revela onde a equipe da Verde está encontrando valor real no Brasil, quais setores oferecem a melhor relação risco-retorno e como o cenário macroeconômico molda as próximas grandes apostas da gestora.

#Podcast #Tecnología#InteligenciaArtificial#Gadgets#AppleHoy exploramos algunas de las noticias y tendencias más interesantes del mundo de la tecnología, el entretenimiento y la innovación. Desde la sorprendente alianza entre Disney y OpenAI, hasta la llegada de una MacBook más barata que podría cambiar el mercado.También analizamos qué está pasando con la Fórmula 1, celebramos el Mario Day y hablamos de gadgets que están generando polémica en el deporte.Además te invitamos al cine para ver Project Hail Mary y revelamos al ganador del Galaxy S26 Ultra.Si te gusta la tecnología, el cine, los gadgets y las historias del mundo digital, este episodio es para ti.

#Chivas se metió entre los mejores tres del torneo después de darle vuelta al Clásico Tapatío y llevarse la victoria.

Apple cerró su semana de lanzamientos con un producto inesperado: la MacBook NEO. Una Mac pensada para estudiantes, usuarios nuevos y para quienes quieren entrar al ecosistema Apple al menor precio posible. ✔️ Desde 599 dólares✔️ Chip A18 Pro (sí, el del iPhone 16 Pro)✔️ macOS completo funcionando sobre arquitectura de iPhone✔️ Pantalla Liquid Retina de 13 pulgadas✔️ 16 horas de autonomía✔️ Diseño ultraliviano con nuevo anodizado✔️ Cámara FaceTime 1080p con Center Stage✔️ Wi-Fi 6 y Bluetooth 6 Pero también tiene limitaciones importantes: ⚠️ Solo 8 GB de RAM⚠️ Sin posibilidad de ampliación⚠️ Desde 256 GB de almacenamiento⚠️ Menos potencia que la MacBook Air M5

Marcado pelo capricho na escolha dos samples e rimas sempre cadenciadas, "Eterno Menino Levado" (2026) transforma a pirraça e a essência da infância em um ato de resistência à vida adulta pragmática. Para mergulhar no processo de criação do trabalho, Cleber Facchi (@cleberfacchi) recebe o rapper Luiz Barata (@luizbarata_) e o produtor Nitcho (@nitcho_prod) em mais uma edição edição do Por Trás Do Disco.Gostou do podcast? Então apoie a gente em ⁠⁠⁠⁠⁠⁠⁠⁠⁠apoia.se/podcastvfsm

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

La gobernadora Maura Healey dio un discurso grande el jueves por la noche sobre sus planes para Massachusetts. Habló sobre hacer que las cosas cuesten menos dinero y enfrentarse . En su charla de 50 minutos, Healey dijo que sabe que las familias tienen problemas para pagar las cosas. “Todo cuesta más ahora – comida, La gobernadora Healey habla sobre hacer la vida más barata y luchar contra Trump Read More » Read the full Article: La gobernadora Healey habla sobre hacer la vida más barata y luchar contra Trump

Quando o país lembra os 7 anos da tragédia de Brumadinho, dois novos incidentes em reservatórios de minas da Vale em Minas Gerais foram registrados nos últimos dias. No final de semana, o principal rio da cidade de Congonhas foi afetado pelo extravasamento de um reservatório. Menos de 24 horas depois, um novo transbordamento ocorreu em outra mina na mesma cidade.A Petrobras anunciou ontem uma redução de 5,2% no preço da gasolina vendida para as distribuidoras no país. A expectativa é que a redução ajude a aliviar a inflação em ano eleitoral, mas não há garantia de que o preço nas bombas também cairá.Saiba mais: https://linktr.ee/primeirocafenoar 

Siga a gente emhttp://youtube.com/@diariodebordopod

Este boletim traz um resumo das principais notícias do dia na análise de Samuel Possebon, editor chefe da TELETIME.TELETIME é a publicação de referência para quem acompanha o mercado de telecomunicações, tecnologia e Internet no Brasil. Uma publicação independente dedicada ao debate aprofundado e criterioso das questões econômicas, regulatórias, tecnológicas, operacionais e estratégicas das empresas do setor. Se você ainda não acompanha a newsletter TELETIME, inscreva-se aqui (shorturl.at/juzF1) e fique ligado no dia a dia do mercado de telecom. É simples e é gratuito.Você ainda pode acompanhar TELETIME nas redes sociais:Linkedin: https://www.linkedin.com/company/teletimenews/Facebook: https://www.facebook.com/Teletime/ Ou entre em nosso canal no Telegram: https://t.me/teletimenews Hosted on Acast. See acast.com/privacy for more information.

En este episodio me senté con Farid Dieck para hablar de algo que todos sentimos pero pocos sabemos poner en palabras: cómo el contenido corto nos está reprogramando el cerebro… y complicando nuestras relaciones.Platicamos de la neuroplasticidad en tiempos de TikTok, de por qué cada vez cuesta más concentrarse, escuchar al otro sin ver el celular y sostener conversaciones profundas sin escapar al scroll infinito. Hablamos de dopamina barata, atención rota y soledad moderna en una era donde nunca habíamos estado tan conectados… y al mismo tiempo tan aislados.Durante la conversación, hablamos qué le está haciendo el contenido corto a tu cerebro, a tu paciencia y a tu capacidad de estar presente, cómo la gratificación inmediata impacta tus vínculos, tus duelos y tu forma de relacionarte con los demás, por qué confundimos “estar en contacto” con “estar conectados de verdad” y qué pequeñas decisiones diarias pueden ayudarte a recuperar foco, profundidad y vínculos más reales.Es una plática sobre mente, emociones y vínculos en la era del algoritmo: incómoda, necesaria y muy actual.

**Habitat for Humanity Canada/Leger Poll (August–September2024):** A recent poll found that 70% of Canadians believe that owning a homehas become impossible. **Statistics Canada (August–September 2024):** The CanadianSocial Survey revealed that nearly half (45%) of Canadians are very concernedabout housing affordability due to rising costs. This concern is even moresignificant among young adults aged 20 to 35, with 59% expressing high levelsof worry. Founded in 1985, Habitat for Humanity Canada is a nationalcharity made up of local Habitat organizations operating in every province andthe North. Through innovative home construction, repairs, financing, skillstraining, and advocacy, they unite people to build homes, communities, andhope. Habitat for Humanity Canada is a member of Habitat for HumanityInternational, a leading global non-profit organization working in over 70countries. Pedro Barata is the President and CEO of Habitat forHumanity Canada. He is a passionate and values-driven leader with two decadesof experience in fostering multi-sector collaborations to create solutions forcommunities. Before joining Habitat in 2024, Pedro served as the executivedirector of the Future Skills Centre, where he led the establishment of anational research impact center and launched various multi-sector innovationpilots across Canada. Barata  joined me thisweek to discuss how Habitat for Humanity Canada is addressing the homeowneraffordability crisis and working to provide more Canadians with safe, decent,and affordable places to call home. For more information, visit:[habitat.ca/en](https://habitat.ca/en)  Follow us on social media: @habitatcanada

O governo federal oficializa nesta terça-feira (9) as mudanças que deixam o processo para tirar a Carteira Nacional de Habilitação (CNH) mais barato. Entre as novidades estão o lançamento de um aplicativo gratuito para o aprendizado teórico, além do fim das aulas obrigatórias em autoescolas. Motoristas sem infrações poderão renovar suas licenças sem custos. Veja também que o Sul enfrenta a ameaça de um ciclone extratropical. Porto Alegre e Serra Gaúcha já registraram danos, e Santa Catarina suspendeu aulas devido a ventos de até 100 km/h. E mais: STF inicia nesta terça-feira (9) o julgamento do núcleo 2 relacionado à tentativa de golpe de Estado de 2023. Os réus são acusados de elaborar a minuta do golpe" e de tentar obstruir votos no Nordeste. Também em Brasília, o Comitê de Política Monetária (Copom) se reúne para decidir a taxa Selic, atualmente em 15%. O resultado dessa reunião será divulgado na quarta-feira (10).

Automóvil, construcción y químico son algunos de los sectores en los que Panza Capital detecta empresas con valoraciones interesantes, como explica Gustavo Trillo.

Siga a gente emhttp://youtube.com/@diariodebordopod

In this episode of The Sound of Economics, host Rebecca Christie sits down with Bruegel's Heather Grabbe and Guntram Wolff to talk about the real costs of a changing climate. With all the fuss over how to manage the climate transition, economists may be overlooking the rising expenses of the changes happening now. From the rising cost of insurance to future housing shocks, evolving weather trends and water scarcity mean the world could be facing big hits to productivity and gross domestic product. What will be the scale of the change? What should economists be studying? How should policymakers act? They discuss what happens when these shocks collide and intensify, rather than occurring one at a time, and how the world can respond.  Related research: Barata da Rocha, M., H. Grabbe and N. Poitiers (2025) ‘Climate risks to global supply chains', Working Paper 20/2025, Bruegel  Claeys, G., M. Le Mouel, S. Tagliapietra, G.B. Wolff and G. Zachmann (2024) The Macroeconomics of Decarbonisation Implications and Policies, Cambridge University Press

A story about why you should always eat your vegetables!

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Hoje o papo é sobre BBB: beleza boa e barata!

CAPA V-DIAMOND BANSK – VIDRO TEMPERADO FOSCO BLINDADO: https://r.vocemaisrico.com/a204b40b43ENTRE NA LISTA DE ESPERA PARA O VIVER DE RENDA: https://r.vocemaisrico.com/275c54667cBitybank é a corretora do Bruno Perini para comprar Bitcoin - abra sua conta: https://r.vocemaisrico.com/0e566a9fff2025 começou carregando as marcas deixadas pelo ano anterior, período em que a bolsa caiu e o dólar disparou, superando a casa dos R$ 6.O cenário que se desenhou neste ano trouxe mudanças significativas: o Banco Central se viu obrigado a elevar os juros ao maior patamar desde 2006, a inflação segue pressionada e dificilmente baterá a meta, enquanto o real ganhou força frente ao dólar.No campo político e internacional, houve a intervenção de Donald Trump na economia, impondo tarifas a países aliados e aplicando ao Brasil alíquotas de até 50% em alguns produtos. No plano interno, embates entre Legislativo e Judiciário e a prisão de um ex-presidente aumentaram a tensão institucional.Diante de tudo isso, como enxergar o cenário até o final de 2025 — e, mais importante, como se preparar para 2026?Para responder estas e mais perguntas e te ajudar a decidir onde investir o seu dinheiro, convidamos os analistas Guilherme Cadonhotto, Felipe Arrais e Ricardo Figueiredo para o episódio nº 256 do podcast Os Sócios. Falaremos sobre estratégias de investimentos, cenário macroeconômico, oportunidades, riscos e muito mais.

Valeria Moy, analista

Quick Synopsis (appears in most podcast apps)In 1772 Portugal, an 18-year-old caregiver named Luísa de Jesus turned the era's child-welfare “foundling wheel” into a murderous money scheme. Before authorities intervened, at least 33 abandoned infants lay buried on Monte Arroio or hidden beneath her cottage floorboards. We expose the systemic cracks, the killer's psychology, and the reforms her crimes set in motion. Episode Breakdown00:00 Opening scene on Monte Arroio04:15 How foundling wheels worked—and failed09:02 Luísa's early life & public façade15:30 The money trail: 600 réis per child22:47 Forensic discoveries: graves & hidden clay pots30:18 Confession to 28 murders36:55 Trial, garrote, and public execution43:20 Child-welfare reforms that followed48:05 Today's take-aways on safeguarding the vulnerableWhy This Case Still ResonatesFirst female serial killer executed in Portugal—and the last woman ever put to death there.Exposed lethal flaws in 18th-century child-protection policy, triggering nationwide reform.Challenges myths that women “only poison”; Luísa strangled newborns for profit.A cautionary tale of how financial incentives plus lax oversight can weaponize charity.Fast FactsYears active: 1771–1772Confirmed victims: 33 infants (one child remains unaccounted for) Method: Strangulation or suffocation within days of state payoutMotive: Collecting stipends meant for wet nursesSentence: Hands severed, garroted; body burned, ashes scattered (1 July 1772)Sources & Further ReadingNational Archives, “Casa da Roda” foundling-wheel records, 1760-1775António Barata, Infanticídio e Justiça em Portugal Setecentista (2018)Royal Chancellery of Coimbra trial transcripts, 1772–1773Stay ConnectedFollow & subscribe on Apple Podcasts, Spotify, or your preferred app.Rate & review—it helps other ethical true-crime fans find us.SEO KeywordsLuísa de Jesus, Foundling Wheel Killer, Coimbra infanticide, 18th-century serial killer, female serial killer history, child-welfare reform, Foul Play podcastMyths & Malice illuminates truth with empathy. Thank you for listening.Support this podcast at — https://redcircle.com/foul-play-crime-series/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Neste episódio do Café com Leite, Bárbara e Babica trazem a divertida e sábia história da formiga e da barata. Enquanto a formiga trabalha sem parar, guardando grão por grão para o futuro, a barata desperdiça, faz bagunça e depois fica na mão. Uma fábula cheia de lições sobre trabalho, planejamento, responsabilidade e independência, contada de um jeito leve e envolvente para crianças e suas famílias. Vamos juntos aprender com esses pequenos insetos?

En este episodio hablamos de ese estímulo rápido y fácil que nos dan las redes sociales, los reels infinitos y las notificaciones que suenan cada cinco minutos. ¿Por qué ya no sabemos ir al baño sin el teléfono? ¿podríamos trotar o salir a caminar sin audífonos? ¿Qué es realmente la dopamina y cómo la sobreestimulación nos está deprimiendo y convirtiendo en zombies? Exploramos la diferencia entre la dopamina buena y la mala, técnicas para usar menos el celular y cómo recuperar la concentración y la motivación real.Únete a Patreon para contenido Exclusivo: https://www.patreon.com/c/laparejamasaburridadelmundo

This is the exclusive audio breakdown section for episode 264 – Medicina Extremadamente Barata en México I Extremely Affordable Medicine in Mexico.Get access to the full interactive transcript, quizzes, and more for this and every episode by joining our community, La Escala, at spanishandgo.com/community.

In this episode, we talk about why Farmacias Similares is such a game-changer for healthcare in Mexico — from super cheap medications to quick, easy doctor visits. We also share a personal story about using their services and have some fun chatting about the famous Doctor Simi. If you've ever wondered how healthcare really works here, or just want to hear a few funny stories, this one's for you!Key Takeaways:How Farmacias Similares revolutionized healthcare affordability in MexicoWhy Doctor Simi became a symbol of trust and happinessThe huge convenience of their walk-in medical consultationsRelevant Links And Additional Resources:171 – Turismo Médico En México – Experiencias Y Costos | Medical Tourism In Mexico – Experiences And CostsLevel up your Spanish with our Podcast MembershipGet the full transcript of each episode so you don't miss a wordListen to an extended breakdown section in English going over the most important words and phrasesTest your comprehension with a multiple choice quizIf you enjoy Learn Spanish and Go, please consider subscribing, rating, and reviewing our podcast on Apple Podcasts, Spotify, Google Podcasts, or Pandora. This helps us reach more listeners like you. ¡Hasta la próximaSupport the show